Ignite Creation Date:
2024-05-06 @ 7:29 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06037941
Status:
RECRUITING
Last Update Posted:
2024-05-01
First Post:
2023-09-08
Brief Title:
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Breathprinting E-Nose Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma MPM Through MPM-Specific Volatile Organic Compounds Detected in Exhalates
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The researchers are doing this study to test the ability of a new technology called breathprinting or electronic nose E-Nose to measure how people respond to standard treatment for malignant pleural mesothelioma MPM The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM They will also look at how changes in peoples E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None